BEST1 Bestrophinopathies: Comprehensive Disease Characteristics Report

Summary

BEST1 bestrophinopathies are a clinically heterogeneous group of inherited retinal dystrophies caused by mutations in the BEST1 gene (chromosome 11q12.3), which encodes bestrophin-1, a pentameric calcium-activated chloride channel (CaCC) predominantly expressed on the basolateral membrane of the retinal pigment epithelium (RPE). Over 250 pathogenic missense mutations and additional frameshift, nonsense, splice-site, and deep intronic variants have been identified, giving rise to five clinically distinct phenotypes: Best Vitelliform Macular Dystrophy (BVMD; OMIM #153700), Autosomal Recessive Bestrophinopathy (ARB; OMIM #611809), Autosomal Dominant Vitreoretinochoroidopathy (ADVIRC; OMIM #193220), Retinitis Pigmentosa type 50 (RP50; OMIM #613194), and Adult-Onset Vitelliform Macular Dystrophy (AVMD). The ClinVar database now contains 1,047 BEST1 variant entries, of which 693 are classified as pathogenic or likely pathogenic.

The core pathophysiology involves disruption of RPE chloride conductance and calcium homeostasis through the BEST1-CaV1.3 L-type calcium channel axis, leading to impaired transepithelial fluid transport, defective phagocytosis of photoreceptor outer segments, accelerated lipofuscin accumulation, and progressive vitelliform material deposition at the macula. In dominant forms, mutant bestrophin-1 exerts dominant-negative effects on pentameric channel assembly, while certain mutations (e.g., p.P233L, p.P346H) undergo Hsp70/CHIP E3 ligase-mediated ubiquitination at Lys149, triggering protein degradation and membrane mislocalization. In recessive forms, biallelic loss-of-function mutations cause more severe and widespread retinal dysfunction, including anterior segment anomalies such as shallow anterior chambers and angle-closure glaucoma.

Therapeutically, there is no approved treatment for bestrophinopathies. However, the first human gene therapy trial (NCT07185256, OPGx-BEST1, Phase 1b/2a) began recruiting in September 2025, and preclinical studies have demonstrated that AAV-mediated BEST1 gene augmentation and CRISPR-Cas9 gene editing can restore chloride channel activity in iPSC-RPE disease models. The largest natural history study of BVMD (n=222 patients) confirms slow visual acuity decline (~0.013 logMAR/year), establishing key endpoints for future clinical trials. Deep intronic variants identified by whole-genome sequencing have resolved the missing heritability problem in Chinese ARB cohorts, underscoring the need for comprehensive genetic testing beyond standard exome approaches.

1. Disease Information

Overview

BEST1 bestrophinopathies are a group of clinically distinct inherited retinal dystrophies caused by mutations in the BEST1 gene (formerly VMD2), which encodes Bestrophin-1, a calcium-activated chloride channel (CaCC) predominantly expressed in the retinal pigment epithelium (RPE). These disorders primarily affect the macula and surrounding retinal regions, leading to progressive central vision loss. The spectrum encompasses at least five clinically recognized phenotypes ranging from juvenile-onset macular dystrophy to retinitis pigmentosa (PMID: 31884648, PMID: 33738427).

"Bestrophinopathies are a group of clinically distinct inherited retinal dystrophies that lead to the gradual loss of vision in and around the macular area. There are no treatments for patients suffering from bestrophinopathies, and no measures can be taken to prevent visual deterioration in those who have inherited disease-causing mutations." (PMID: 31884648)

Key Identifiers

Common Synonyms and Alternative Names

• Best vitelliform macular dystrophy (BVMD)
• Best disease / Best macular dystrophy (BMD)
• Vitelliform macular dystrophy type 2 (VMD2)
• Autosomal recessive bestrophinopathy (ARB)
• Autosomal dominant vitreoretinochoroidopathy (ADVIRC)
• Retinitis pigmentosa 50 (RP50)
• Adult-onset vitelliform macular dystrophy (AVMD) (when BEST1-related)

Information Source

This report is derived from aggregated disease-level resources including primary literature (108 PubMed-indexed publications), OMIM, Orphanet, ClinVar, GeneReviews, and published clinical cohort studies. The largest patient-level datasets include the BVMD natural history study (n=222; PMID: 38278445) and ARB cohort studies (PMID: 41421761; PMID: 33039401).

2. Etiology

Disease Causal Factors

BEST1 bestrophinopathies are purely genetic disorders caused by mutations in the BEST1 gene located at chromosome 11q12.3. No environmental or infectious causes are known.

Risk Factors

Genetic Risk Factors

• Causal variants: Over 250 distinct pathogenic mutations identified in BEST1, predominantly missense variants (PMID: 31570112, PMID: 36378562).
• Mutation hotspots: Variants cluster in functionally critical regions including the transmembrane domains (TM2-TM4), calcium-binding regions, and the cytoplasmic domain (exons 2-8). Variant c.898G>A was identified as a hotspot in the Chinese population (PMID: 32278767).
• Deep intronic variants (DIVs): c.1101-491A>G (pseudoexon insertion), c.867+97G>A (intron retention, Chinese founder), c.867+97G>T resolved missing heritability in 20/63 Chinese ARB families (PMID: 37747403).
• Founder variants: Egyptian founder variant c.365G>C (p.Arg122Pro) in 12 patients from 9 unrelated consanguineous families (PMID: 40414863).

"A total of 9 variants on the BEST1 gene were identified, containing 7 missense variants, 1 nonsense variant, and 1 frameshift variant" (PMID: 36378562)

Environmental Risk Factors

No environmental risk factors are established for bestrophinopathies. The disease is entirely genetically determined. Age is the primary non-genetic factor affecting disease progression and visual acuity outcomes.

Protective Factors

• Genetic: Variable penetrance in some families suggests modifier genes, though none identified. In the Slovenian cohort, mutation p.Arg105Gly showed incomplete clinical penetrance (PMID: 27775230).
• Environmental: No established environmental protective factors.

Gene-Environment Interactions

No gene-environment interactions have been documented. Variable expressivity and penetrance are thought to reflect genetic background differences rather than environmental influences.

3. Phenotypes

Best Vitelliform Macular Dystrophy (BVMD) - The Classic Phenotype

BVMD progresses through recognized clinical stages:

Phenotype Characteristics

• Age of onset: Typically childhood to adolescence (3-15 years), though can present in adulthood (PMID: 29115605)
• Severity: Variable, from asymptomatic carriers with only abnormal EOG to severe central vision loss
• Progression: Slowly progressive over decades; mean annual BCVA loss 0.013 logMAR/year
• Frequency: Characteristic bilateral "egg-yolk" lesion in most symptomatic individuals; rare unilateral presentation documented (PMID: 40556259, PMID: 39992563)

The largest natural history study (222 patients, 141 families, mean follow-up 9.7 years) reported: "Mean BCVA was 0.37 logarithm of the minimum angle of resolution (logMAR; Snellen equivalent, 20/47) for the right eye and 0.33 logMAR (Snellen equivalent, 20/43) for the left eye at presentation, with a mean annual loss rate of 0.013 logMAR and 0.009 logMAR, respectively" (PMID: 38278445).

Structural progression: "Mean central retinal thickness on OCT at baseline was 337.2 um for the right eye and 341.1 um for the left eye, with a mean annual thickness loss of 5.7 and 5.2 um, respectively" (PMID: 40086732).

Key Symptoms and Signs

1. Central visual loss (HP:0007663) - Progressive, typically presenting in first or second decade
2. Vitelliform macular lesion (HP:0007677) - Bilateral yellow subretinal deposits
3. Reduced EOG light rise (HP:0030453) - Arden ratio <1.5; hallmark finding
4. Metamorphopsia (HP:0012508) - Distortion of central vision
5. Reduced color vision - Tritan-axis deficit in ~50% of ARB patients (PMID: 34015078)
6. Subretinal fluid accumulation (HP:0031526) - Common in BVMD and ARB
7. Choroidal neovascularization (HP:0011506) - Complication in advanced stages

Autosomal Recessive Bestrophinopathy (ARB)

ARB presents with distinct additional features:

"Anterior features included shallow anterior chambers (16/17), ciliary pronation (16/17), iris bombe (13/17), iridoschisis (2/17), iris plateau (1/17), narrow angles (16/17) and reduced axial lengths (16/17)." (PMID: 39048936)

ARB visual decline: "Mean presenting VA was 0.52 +/- 0.36 logarithm of the minimum angle of resolution (logMAR), and final VA was 0.81 +/- 0.75 logMAR. The mean rate of change in VA was 0.05 +/- 0.13 logMAR/year." (PMID: 33039401)

Autosomal Dominant Vitreoretinochoroidopathy (ADVIRC)

ADVIRC is an extremely rare bestrophinopathy with distinctive developmental and degenerative features:

"Clinical features observed included angle closure glaucoma (n = 2), microcornea with shallow anterior chamber (n = 1), iris dysgenesis (n = 2), cataracts (n = 4), classical peripheral concentric band of retinal hyperpigmentation (n = 5), and optic nerve dysplasia (n = 1)." (PMID: 21072067)

"This report highlights the high phenotypic variability of autosomal dominant vitreoretinochoroidopathy, which may be misdiagnosed, especially in advanced forms with severe generalized photoreceptor dysfunction mimicking retinitis pigmentosa." (PMID: 29370033)

Retinitis Pigmentosa 50 (RP50)

RP50 presents with classic RP features including bone spicule pigmentation (HP:0000510), progressive visual field constriction (HP:0001133), night blindness (HP:0000662), reduced ERG amplitudes, and cystoid macular edema (HP:0040049) responding to oral acetazolamide (PMID: 29503890).

Quality of Life Impact

• Psychosocial burden scores in inherited retinal diseases exceed a mean of 6/10 across all domains (PMID: 40993143)
• Central vision loss significantly impacts reading, driving, and face recognition
• Most BVMD patients retain peripheral vision, maintaining independence for decades
• ARB patients face additional risk of acute vision loss from angle-closure glaucoma

4. Genetic/Molecular Information

Causal Gene

"Human bestrophin-1 (hBest1) is a calcium-activated chloride channel from the retinal pigment epithelium... KpBest is a pentamer that forms a five-helix transmembrane pore, closed by three rings of conserved hydrophobic residues, and has a cytoplasmic cavern with a restricted exit." (PMID: 25324390)

Pathogenic Variants

Variant Types and Classification

• Missense variants: Most common (~85-90%); predominantly in exons 2-8
• Nonsense variants: Less common, typically in ARB
• Frameshift variants: Associated with ARB when biallelic
• Splice-site variants: Including deep intronic variants (DIVs)

ClinVar statistics (May 2026): 1,047 total BEST1 variant entries: 455 pathogenic, 238 likely pathogenic (693 combined P/LP). This represents one of the largest variant databases for any inherited macular dystrophy gene.

Notable Variants

Deep Intronic Variants (Missing Heritability)

"Subsequent WGS, combined with supplementary Sanger sequencing, revealed three missing DIVs (c.1101-491A>G, c.867+97G>A, and c.867+97G>T) in 20 families. The novel DIV c.1101-491A>G caused an abnormal splicing resulting in a 204-nt pseudoexon (PE) insertion, whereas c.867+97G>A/T relatively strengthened an alternative donor site, resulting in a 203-nt intron retention (IR)." (PMID: 37747403)

Functional Consequences

• Dominant mutations (BVMD, ADVIRC): Primarily dominant-negative — mutant subunits incorporate into pentameric channel, disrupting function. Some mutations (p.P233L, p.P346H) undergo Hsp70/CHIP ubiquitination at Lys149: "Mutant bestrophin-1 proteins p.P346H and p.P233L undergo ubiquitination and degradation, preventing their localization to the cell membrane of MDCK II cells and the RPE of zebrafish, thereby reducing chloride channel activity." (PMID: 41456629)
• Recessive mutations (ARB, RP50): Loss-of-function — biallelic null or hypomorphic alleles that eliminate or severely reduce channel activity.

Modifier Genes

No modifier genes conclusively identified. Intrafamilial phenotypic variability strongly suggests genetic modifiers. "The features and combinations of different BEST1 mutations as well as epistatic effects may influence phenotype expression." (PMID: 25489231)

Protein Interaction Network (STRING-DB)

BEST1 also interacts directly with CaV1.3 (CACNA1D) L-type calcium channel (PMID: 26427483).

Epigenetic and Chromosomal Information

No specific epigenetic alterations or chromosomal abnormalities reported. All pathogenic events occur at the nucleotide level.

5. Environmental Information

Environmental Factors

No environmental toxins, radiation, or occupational exposures are causative or modifying. The disease is entirely genetic.

Lifestyle Factors

No specific lifestyle factors established. General retinal-protective measures (UV protection, antioxidant supplementation) may be theoretically beneficial but lack specific evidence.

Infectious Agents

Not applicable.

6. Mechanism / Pathophysiology

Molecular Pathways

Primary: Calcium-Activated Chloride Channel Dysfunction

Bestrophin-1 forms a pentameric CaCC on the basolateral membrane of RPE cells, activated by intracellular Ca2+ at ~150-200 nM. The channel conducts Cl- and HCO3- ions, regulating transepithelial potential and fluid transport.

"Human bestrophin-1 (hBest1) is a calcium-activated chloride channel from the retinal pigment epithelium... KpBest is a pentamer that forms a five-helix transmembrane pore" (PMID: 25324390)

"Mutations in BEST1, encoding Bestrophin-1 (Best1), cause Best vitelliform macular dystrophy (BVMD) and other inherited retinal degenerative diseases. Best1 is an integral membrane protein localized to the basolateral plasma membrane of the retinal pigment epithelium (RPE). Data from numerous in vitro and in vivo models have demonstrated that Best1 regulates intracellular Ca2+ levels." (PMID: 25878489)

Secondary: BEST1-CaV1.3 Calcium Channel Axis

"Previously we showed that bestrophin-1 interacts with L-type Ca2+ channels of the CaV1.3 subtype and that the endogenously expressed bestrophin-1 is required for intracellular Ca2+ regulation. A hallmark of Best's disease is the fast lipofuscin accumulation occurring already at young ages." (PMID: 26427483)

This interaction modulates phagocytosis of photoreceptor outer segments (POS). CaV1.3 expression is diurnally regulated (higher in afternoon), and CaV1.3-/- mice show shifted circadian POS phagocytosis, linking BEST1 to circadian RPE function.

Cellular Processes

1. Impaired Fluid Transport (GO:0042044)

"Fluid transport from apical to basal was significantly decreased in ARB iPSC-RPE compared with BD iPSC-RPE or control iPSC-RPE." (PMID: 32882766)

2. Impaired Phagocytosis (GO:0006909)

"When tested for the ability to phagocytose photoreceptor outer segments, ARB iPSC-RPE exhibited impaired internalization. These data suggest that impaired phagocytosis is a trait common to the bestrophinopathies." (PMID: 29540715)

3. Epithelial-Mesenchymal Transition (GO:0001837) and Inflammation

"Gene Set Enrichment Analysis confirmed that ARB iPSC-RPE exhibited significant enrichments of epithelial-mesenchymal transition gene set and TNF-alpha signaling via NF-kappaB gene set compared to control iPSC-RPE or BD iPSC-RPE." (PMID: 32882766)

Protein Quality Control: Hsp70/CHIP Ubiquitination Pathway

"Lys149 was identified as the site responsible for ubiquitination of p.P346H- and p.P233L-bestrophin-1, mediated by Hsp70 and the C-terminal Hsp70-interacting protein (CHIP). Mutant bestrophin-1 proteins p.P346H and p.P233L undergo ubiquitination and degradation, preventing their localization to the cell membrane of MDCK II cells and the RPE of zebrafish, thereby reducing chloride channel activity." (PMID: 41456629)

Causal Chain: Mutation to Clinical Disease

BEST1 mutation
    |
    v
Dysfunctional Bestrophin-1 channel
(reduced Cl- conductance + altered Ca2+ signaling via BEST1-CaV1.3 axis)
    |
    +---> Impaired transepithelial fluid transport --> Subretinal fluid accumulation
    |
    +---> Defective POS phagocytosis --> Lipofuscin/vitelliform material accumulation
    |
    +---> EMT activation + NF-kB/TNF-alpha signaling --> RPE dysfunction
    |
    v
Progressive RPE atrophy --> Secondary photoreceptor degeneration --> Vision loss

Lipid Membrane Interactions

"Interactions between hBest1, sphingomyelins, phosphatidylcholines and cholesterol are crucial for hBest1 association with cell membrane domains and its biological functions." (PMID: 33451008)

Purinergic Signaling

"hBest1 mutants that are known to cause autosomal dominant macular dystrophy (Best disease) did not produce a Cl- current. Bestrophins were colocalized and showed molecular and functional interaction in HEK293 cells." (PMID: 19130075)

GO Terms

Molecular Function: - GO:0005229 - intracellularly calcium-gated chloride channel activity - GO:0005254 - chloride channel activity - GO:0160133 - bicarbonate channel activity - GO:0042802 - identical protein binding (homo-pentamer formation)

Biological Process: - GO:1902476 - chloride transmembrane transport - GO:0006821 - chloride transport - GO:0050908 - detection of light stimulus involved in visual perception - GO:0006909 - phagocytosis - GO:0042044 - fluid transport - GO:0001837 - epithelial to mesenchymal transition (disease mechanism) - GO:0006954 - inflammatory response (TNF-alpha/NF-kappaB in ARB)

Cellular Component: - GO:0016323 - basolateral plasma membrane (primary localization) - GO:0034707 - chloride channel complex - GO:0098857 - membrane microdomain (lipid rafts) - GO:0005783 - endoplasmic reticulum

Cell Types (CL Terms)

• CL:0002586 - retinal pigment epithelial cell (primary)
• CL:0000604 - retinal rod cell (secondary degeneration)
• CL:0000573 - retinal cone cell (secondary degeneration)

Chemical Entities (CHEBI Terms)

7. Anatomical Structures Affected

Organ Level

• Primary organ: Eye (UBERON:0000970)
• Primary structure: Retina (UBERON:0000966), specifically the macula (UBERON:0000053)
• Secondary involvement: Anterior segment (in ARB and ADVIRC)
• Body system: Visual system (UBERON:0002104)

Tissue and Cell Level

Subcellular Level

• Basolateral plasma membrane (GO:0016323) - BEST1 primary localization
• Endoplasmic reticulum (GO:0005783) - BEST1 also localizes here; misfolded mutants accumulate
• Phagolysosomes (GO:0001891) - Impaired in bestrophinopathies

Localization

• Bilateral involvement is the rule; rare unilateral presentations documented (PMID: 39992563; PMID: 40556259)
• BVMD primarily affects fovea/macula; ARB shows diffuse posterior pole to panretinal involvement; ADVIRC characteristically affects the peripheral retina

8. Temporal Development

Onset

Progression

BVMD: Slow progression through well-defined stages over decades. Mean annual BCVA loss: 0.013 logMAR/year (right eye), 0.009 logMAR/year (left eye) over 9.7-year mean follow-up. Mean central retinal thickness loss: 5.7 um/year (PMID: 38278445; PMID: 40086732).

ARB: More rapid progression. Rate of VA change: 0.05 logMAR/year. SW-AF severity grading: 21% grade 1 (isolated macular), 44% grade 2 (multifocal/diffuse posterior pole), 35% grade 3 (panretinal) (PMID: 41421761).

Disease duration: Chronic lifelong. No spontaneous remission.

Critical Periods

• Childhood/adolescence: Period of vitelliform lesion appearance in BVMD
• CNV development: Can occur at any stage; treatable if detected early; reported in children as young as 8 years (PMID: 26225154)

9. Inheritance and Population

Epidemiology

• BVMD prevalence: Estimated 1:10,000 to 1:67,000 (varies by population)
• ARB prevalence: Much rarer; estimated <1:100,000
• Overall: Among the most common inherited macular dystrophies

Inheritance Patterns

"Recessively inherited VMD (arVMD) has been reported, suggesting that dominant and recessive BEST1-related retinopathies represent a single disease spectrum." (PMID: 34015078)

Penetrance and Expressivity

• Penetrance: Incomplete in many families. Some heterozygous carriers have only abnormal EOG without fundus lesions. "Family study confirmed the variable penetrance and expressivity of the disease." (PMID: 31570112)
• Expressivity: Highly variable. Within a single family, different stages and severity observed with the same mutation.

Founder Effects

• c.867+97G>A: Chinese ARB founder variant (PMID: 37747403)
• c.365G>C (p.Arg122Pro): Egyptian ARB founder variant (PMID: 40414863)

Population Demographics

• Worldwide distribution; no specific ethnic predilection for BVMD
• Sex ratio: Approximately 1:1 (slight male predominance in largest cohort, 57.2%, likely ascertainment bias)
• Consanguinity: Significantly increases ARB risk (PMID: 21738390; PMID: 40414863)

10. Diagnostics

Clinical Tests

Electro-oculogram (EOG)

Gold standard functional test. Measures the Arden ratio (light peak / dark trough). Normal >1.65-1.80; BVMD <1.5; ARB often <1.1. Reduced bilaterally even with unilateral fundus lesions. "The Arden ratio was significantly lower in ARB patients and in eyes with stage 5 of BVMD." (PMID: 34327816)

Optical Coherence Tomography (OCT)

Demonstrates subretinal hyperreflective material, subretinal fluid, RPE detachment/irregularity, and progressive outer retinal thinning.

Fundus Autofluorescence (FAF)

Hyperautofluorescent vitelliform deposits; hypoautofluorescent atrophic areas. Useful for distinguishing ARB from BVMD and for staging.

Electroretinography (ERG)

Full-field ERG typically normal in BVMD; reduced in ARB. Helps distinguish from generalized retinal dystrophies.

Deep Learning/AI Diagnosis

~90% accuracy in differentiating BVMD from AVMD on OCT and BAF imaging (PMID: 35882966).

Genetic Testing

Recommended approach: 1. First-line: Targeted BEST1 sequencing (all 11 exons + flanking intronic regions) 2. If negative: Gene panel for inherited macular dystrophies 3. Complex cases: WES or WGS (critical for deep intronic variants)

"Subsequent WGS, combined with supplementary Sanger sequencing, revealed three missing DIVs in 20 families." (PMID: 37747403)

Third-generation sequencing (PacBio SMRT) has also been successfully used (PMID: 38619684).

Differential Diagnosis

Screening

• Cascade screening of family members via EOG and genetic testing
• No population-level screening currently recommended

MAXO Terms

• MAXO:0010034 (electro-oculography)
• MAXO:0010033 (electroretinography)
• MAXO:0010032 (optical coherence tomography)
• MAXO:0000079 (genetic testing)

11. Outcome / Prognosis

Survival and Mortality

Life expectancy is normal. Bestrophinopathies are purely ocular with no systemic manifestations and no disease-specific mortality.

Morbidity and Function

• BVMD: Many maintain functional vision (>20/40) for decades. Mean annual BCVA loss only 0.013 logMAR/year.
• ARB: More rapid decline. Mean presenting VA: 0.52 logMAR (~20/66); final VA: 0.81 logMAR (~20/130); rate: 0.05 logMAR/year (PMID: 33039401).
• Complications: CNV (any stage, treatable with anti-VEGF); angle-closure glaucoma (29% in ARB; PMID: 41421761); macular hole (rare).

Prognostic Factors

• Zygosity: Biallelic (ARB) worse than heterozygous (BVMD)
• Disease stage: Advanced stages (4-5) have poorer outcomes
• SW-AF grade: Higher grades in ARB correlate with more extensive dysfunction
• CNV development: If treated promptly, outcomes can be reasonable

12. Treatment

Current Standard of Care

No approved disease-modifying treatment. Management is supportive and complication-directed.

Pharmacotherapy

Anti-VEGF Therapy (for CNV)

• Bevacizumab (off-label intravitreal): Effective for CNV regression in BVMD and ARB (PMID: 20195045; PMID: 26225154; PMID: 36729806)
• Ranibizumab, Aflibercept: Also used

Photodynamic Therapy (PDT)

Long-term safety demonstrated in pediatric BVMD with CNV (PMID: 25675349).

Carbonic Anhydrase Inhibitors

Oral acetazolamide for cystoid macular edema in RP50 (PMID: 29503890).

Advanced Therapeutics: Gene Therapy

Preclinical evidence: "Gene augmentation in iPSC-RPE fully restored BEST1 calcium-activated chloride channel activity and improved rhodopsin degradation in an iPSC-RPE model of recessive bestrophinopathy as well as in two models of dominant Best disease caused by different mutations in regions encoding ion-binding domains. A third dominant Best disease iPSC-RPE model did not respond to gene augmentation, but showed normalization of BEST1 channel activity following CRISPR-Cas9 editing of the mutant allele." (PMID: 32707085)

Canine studies: "the rAAV2/2 vector serotype carrying either GFP reporter or BEST1 transgene under control of human VMD2 promoter was safe, and enabled specific transduction of the RPE cell monolayer that was stable for up to 6 months post injection" (PMID: 24143172)

Advanced Therapeutics: Gene Editing

CRISPR/Cas9 and Cas12 correction using lipoplexes achieved HDR in iPSC-RPE from Best disease patients (PMID: 41827889). Particularly relevant for dominant-negative mutations non-responsive to gene augmentation.

Active Clinical Trials

Supportive Care

• Low vision aids and rehabilitation (MAXO:0000127)
• Regular monitoring for CNV and glaucoma
• Glaucoma management for angle-closure complications
• Genetic counseling (MAXO:0000950)

MAXO Terms

• MAXO:0001001 (gene therapy)
• MAXO:0001085 (genome editing therapy)
• MAXO:0001298 (intravitreal injection)
• MAXO:0000015 (photodynamic therapy)
• MAXO:0000127 (low vision rehabilitation)
• MAXO:0000950 (genetic counseling)

13. Prevention

Primary Prevention

As a genetic disorder, primary prevention is limited to reproductive counseling: - Genetic counseling for at-risk families - Preimplantation genetic testing (PGT) for families with known pathogenic variants - Prenatal diagnosis technically possible but not routinely performed

Secondary Prevention (Early Detection)

• Cascade genetic testing of at-risk family members
• EOG screening in family members of affected individuals
• Regular ophthalmologic monitoring for early CNV and glaucoma detection

Tertiary Prevention (Complication Prevention)

• Regular IOP monitoring in ARB for angle-closure glaucoma
• Prophylactic laser peripheral iridotomy in ARB patients with narrow angles
• Amsler grid self-monitoring for early CNV detection
• Patient education on symptoms requiring urgent evaluation

Genetic Counseling

• BVMD/ADVIRC (AD): 50% recurrence risk to offspring
• ARB/RP50 (AR): 25% recurrence risk to siblings of affected individual
• Variable penetrance and expressivity must be discussed
• Carrier testing available for recessive forms

14. Other Species / Natural Disease

Canine Bestrophinopathies

Canine multifocal retinopathy (cmr) is the best-characterized veterinary counterpart:

Canine cmr recapitulates human bestrophinopathy features and has been instrumental for gene therapy development (PMID: 24143172; PMID: 33606121).

BEST1 Orthologs

Comparative Biology

BEST1 is highly conserved across vertebrates and invertebrates. The calcium-activated chloride channel function is conserved from bacteria to humans (PMID: 25324390). Not zoonotic; not transmissible between species.

15. Model Organisms

Mouse Models

• Best1-Cre transgenic mice: Standard tool for RPE-specific conditional gene targeting (used for autophagy, potassium channel, Yap1, glucose transport studies: PMID: 26075877; PMID: 30009826; PMID: 32223016; PMID: 30462537)
• Limitation: Mice lack a true macula, limiting translational relevance for macular-predominant disease

Canine Models

Naturally occurring cmr1/cmr2/cmr3 — most clinically relevant large-animal model for therapeutic development. AAV gene therapy safety and efficacy demonstrated (PMID: 24143172).

Zebrafish Models

Used for in vivo validation of mutant pathogenicity. Overexpression of human BEST1 mutants (p.P233L, p.P346H) demonstrated mislocalization and retinal structural disruption (PMID: 41456629).

Drosophila Models

dBest1 identified as the Drosophila Cl_swell channel in genome-wide RNAi screen (PMID: 23056495). Currents regulated by CaMKII-dependent phosphorylation (PMID: 23554946). Human disease mutation W94C reduced endogenous Cl_swell current.

iPSC-RPE Models (In Vitro)

Most physiologically relevant disease model:

"This protocol describes how to generate human RPEs bearing BEST1 disease-causing mutations by induced differentiation from human pluripotent stem cells... provides a very powerful disease-in-a-dish model for BEST1-associated retinal conditions." (PMID: 30199040)

Model Limitations

• Mouse: Lacks macula; mild phenotype
• Canine: Expensive; limited genetic manipulation tools
• Zebrafish: No fovea; overexpression may not fully recapitulate endogenous disease
• Drosophila: dBest1 has distinct swell-activation; limited disease relevance
• iPSC-RPE: Lacks complex retinal architecture and photoreceptor interactions

Key Findings Summary

F001: BEST1 Pentameric CaCC Structure

Crystal structure of bacterial homolog KpBest1 revealed pentameric architecture. BEST1 is a Ca2+-activated Cl- channel expressed on basolateral membrane of RPE (PMID: 25324390; PMID: 25878489).

F002: Five Distinct Bestrophinopathy Phenotypes

Over 200 pathogenic mutations cause BVMD, ARB, ADVIRC, RP50, and AVMD. Biallelic variants cause more severe phenotypes, supporting a disease spectrum concept (PMID: 31884648; PMID: 34015078).

F003: ARB Natural History Quantified

34 ARB patients: median baseline age 32 years, 29% with PAC, mean VA decline 0.05 logMAR/year. Anterior segment features in >90% of Chinese patients (PMID: 41421761; PMID: 33039401; PMID: 39048936).

F004: Gene Therapy Preclinical Promise

AAV augmentation restored CaCC activity in 3/4 iPSC-RPE models; CRISPR rescued the fourth dominant-negative model. Canine rAAV2/2-BEST1 showed stable 6-month RPE transduction (PMID: 32707085; PMID: 24143172).

F005: iPSC-RPE Reveals Impaired Fluid Transport and Phagocytosis

ARB iPSC-RPE showed decreased fluid transport, EMT/NF-kB pathway enrichment, and impaired POS internalization (PMID: 32882766; PMID: 29540715).

F006: First Human Gene Therapy Trial

NCT07185256 (OPGx-BEST1, Phase 1b/2a) recruiting since September 2025. Subretinal AAV injection for BVMD/ARB.

F007: ADVIRC Clinical Characterization

Developmental anomalies (microcornea, iris dysgenesis, optic nerve dysplasia) plus peripheral retinal hyperpigmentation. High variability; may mimic RP (PMID: 21072067; PMID: 29370033).

F008: BEST1-CaV1.3 Phagocytosis Regulation

Bestrophin-1 interacts with CaV1.3 to regulate calcium and POS phagocytosis. CaV1.3 is diurnally regulated, linking to circadian RPE function (PMID: 26427483; PMID: 31930599).

F009: Deep Intronic Variants Resolve Missing Heritability

WGS identified three DIVs in Chinese ARB, resolving 20/63 pedigrees. c.867+97G>A is a Chinese founder allele (PMID: 37747403).

F010: ClinVar Variant Landscape

1,047 BEST1 variants; 693 P/LP. STRING-DB top partners: RPE65 (0.891), PRPH2 (0.868), ABCA4 (0.811).

F011: Ubiquitination Mechanism

Hsp70/CHIP E3 ligase ubiquitinates mutant BEST1 at Lys149 (p.P233L, p.P346H), causing degradation and membrane mislocalization. Validated in MDCK II cells and zebrafish (PMID: 41456629).

F012: BVMD Natural History (Largest Cohort)

222 patients, 141 families: mean presenting BCVA 0.37 logMAR, annual loss 0.013 logMAR/year, central retinal thickness 337 um declining 5.7 um/year (PMID: 38278445; PMID: 40086732).

Evidence Base

Key Literature

Limitations and Knowledge Gaps

1. Incomplete genotype-phenotype correlations: Despite 1,047 known variants, the relationship between specific mutations and clinical severity remains poorly understood.
2. Unknown modifier genes: Intrafamilial variability strongly suggests genetic modifiers, but none have been identified.
3. Limited natural history data for rare phenotypes: ADVIRC, RP50, and AVMD lack systematic longitudinal studies.
4. Absence of validated biomarkers: No blood-based or non-invasive biomarkers exist for disease monitoring.
5. Mouse model limitations: Mice lack a true macula, limiting translational relevance.
6. Gene therapy for dominant mutations: Optimal approach (augmentation vs. editing vs. knockdown-and-replace) undefined for each mutation class.
7. Long-term gene therapy safety: First human trial just begun; long-term outcomes and pediatric application remain unknown.
8. Environmental modifiers: Whether light exposure, nutrition, or other factors modify progression has not been studied.
9. Missing molecular diagnoses: Some ARB families remain genetically unresolved even with WGS.
10. Quality of life data: No disease-specific patient-reported outcome measures exist.

Proposed Follow-up Experiments / Actions

High Priority

1. Monitor NCT07185256 (OPGx-BEST1) trial outcomes: Phase 1b/2a results will define safety and preliminary efficacy of subretinal AAV-BEST1 gene therapy.
2. Expand WGS-based genetic testing: Implement WGS as standard for genetically unsolved ARB cases, particularly in populations with known deep intronic founder variants.
3. Develop mutation-specific therapeutic algorithms: Classify BEST1 mutations into gene augmentation-responsive vs. gene editing-requiring categories using iPSC-RPE modeling.
4. Investigate Hsp70/CHIP pathway as therapeutic target: Small-molecule chaperones or proteasome modulators that rescue mutant bestrophin-1 trafficking.

Medium Priority

1. Genome-wide modifier gene search: GWAS or WGS in large bestrophinopathy families with variable penetrance.
2. Develop bestrophinopathy-specific PROs: Create and validate disease-specific quality-of-life instruments for clinical trials.
3. Longitudinal ADVIRC and RP50 natural history registries.
4. Pharmacological chaperone screening for compounds promoting mutant bestrophin-1 folding.

Lower Priority

1. Single-cell transcriptomics of patient iPSC-RPE to characterize cellular heterogeneity.
2. CRISPR base editing approaches for common BEST1 missense mutations without requiring HDR.

Ontology Summary Table

Report generated: 2026-05-05. Based on systematic review of 108 PubMed-indexed publications and 12 confirmed findings across 5 research iterations. 47 primary literature citations with PMIDs. 86+ ontology term annotations across HPO, GO, CL, UBERON, CHEBI, MAXO, and MONDO.